Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2026-05-27 Interim / Quarterly Rep…
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Therapeutics - Quarterly Report Q1 2026 - Attachment: 260527 Nykode Quarterly Report Q1 2026.pdf
Interim / Quarterly Report Classification · 99% confidence The document is titled “INTERIM REPORT” and “QUARTERLY REPORT Q1 2026” and contains unaudited financial results, key financial figures for the quarter, business updates, and detailed income statement and balance sheet items. It is a comprehensive report for a period shorter than a full fiscal year with substantive financial data, matching the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-27 English
Nykode Therapeutics - Quarterly Report Q1 2026
Earnings Release Classification · 85% confidence The document is a press release announcing Nykode Therapeutics’ unaudited Q1 2026 financial results, providing a link to the full report and details of an upcoming webcast. It does not include substantive financial statements itself, only a summary and directions to the published report, fitting the definition of an Earnings Release rather than the full Interim Report or mere Report Publication Announcement. Q1 2026
2026-05-27 English
Nykode Therapeutics – Invitation to Q1 2026 Financial Results Presentation - Attachment: 260518_Nykode Therapeutics_Q1 2026 Invitation to webcast__.pdf
Report Publication Announcement Classification · 85% confidence The document is a corporate announcement inviting investors to the forthcoming release of the company’s Q1 2026 financial results and webcast presentation. It contains no actual financial data or result highlights, only the timing, webcast details, and links where the report will be published. Per the "menu vs meal" rule, this is an announcement of the report release rather than the report itself. Therefore it is a Report Publication Announcement.
2026-05-18 English
Nykode Therapeutics – Invitation to Q1 2026 Financial Results Presentation
Report Publication Announcement Classification · 93% confidence The document is a brief announcement inviting investors to a webcast presentation of the company’s upcoming Q1 2026 financial results and stating when and where the report will be released. It does not contain the actual financial data or serve as the earnings release itself, but simply announces the timing and access details for the report. Therefore, it qualifies as a Report Publication Announcement.
2026-05-18 English
Nykode Therapeutics ASA - Minutes of Annual General Meeting - Attachment: 260513 - Nykode AGM Minutes.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is the official minutes (protokoll) of Nykode Therapeutics ASA’s Annual General Meeting held on May 13, 2026. It records agenda items, shareholder resolutions, and detailed vote counts (for/against/abstain) on each item. While it covers governance approvals and board elections, its primary function is to declare the official voting results of the shareholder meeting. Therefore, it best fits the “Declaration of Voting Results & Voting Rights Announcements” category (DVA).
2026-05-13 Norwegian Bokmål
Nykode Therapeutics ASA - Minutes of Annual General Meeting
Report Publication Announcement Classification · 72% confidence The document is a short notice summarizing that the minutes of the Annual General Meeting (AGM) are attached, without including the detailed minutes themselves. Under the “menu vs meal” rule, it announces the publication of a report (the AGM minutes) rather than containing substantive report content. Therefore, it is classified as a Report Publication Announcement (RPA).
2026-05-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.